In the News

BD Receives FDA Clearance for a Novel Infusion Set with BD FlowSmart Technology to Enhance the Use of Insulin Pumps
By JDRF Canada
May 14, 2015

BD Medical, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has received 510(k) clearance from the U.S. Food and Drug Administration for a new insulin infusion set with BD FlowSmartTM  technology. 

Read More
14-Year-Old from Vancouver to Represent Canada at JDRF 2015 Children’s Congress
By JDRF Canada
May 6, 2015

Jack, 14 of Vancouver, has big plans for this summer. He has been selected by JDRF to join 160 other children from around the world in Washington, D.C., to remind U.S. Members of Congress of the vital need to continue supporting research that aims to reduce the burden they all share of living with type 1 diabetes (T1D), until a cure is found.

Read More
Tags: Children’s Congress, advocacy, type 1 diabetes, advocates, Washington D.C
Two-year $300 Million Extension of the Special Diabetes Program Allows for the Continuation of Promising Ongoing Clinical Trials
By JDRFI
April 20, 2015

The U.S. Senate overwhelmingly approved legislation last night for a two-year extension of the Special Diabetes Program (SDP)—an initiative that accounts for roughly one-third of all Federally-funded type 1 diabetes (T1D) research in the United States. The decision comes on the heels of the strong bipartisan approval of the legislation on March 26 by the U.S. House of Representatives, and will extend SDP funding for the National Institutes of Health (NIH) at the current level of $150 million, per year, as part of the ‘Medicare Access and CHIP Reauthorization Act of 2015’ (H.R. 2). The President is expected to sign the legislation into law today.

Read More
REGiMMUNE Announces Collaboration with JDRF and Pfizer Inc. for Type 1 Diabetes Prevention and Treatment Promoting Regulatory T-Cells
By JDRFI
April 15, 2015

REGiMMUNE Corporation (RGI) and JDRF today announced a partnership, along with financial assistance and scientific expertise from Pfizer Inc., for a research collaboration to develop an antigen-specific immunotherapy utilizing RGI’s proprietary αGalCer/liposome platform for immunological tolerance for the treatment of type 1 diabetes (T1D). Under the terms of the collaboration, REGiMMUNE will develop an antigen-specific therapeutic liposome that potentially prevents or delays the onset of T1D and induce immunologic tolerance. 

Read More
JDRF in the Globe and Mail, April 1, 2015: Improving the chances for healthy pregnancies.
By JDRF Canada
April 1, 2015

JDRF showcases the CONCEPPT trial, including quotes from Dr. Lois Donovan, Medical Director of diabetes in pregnancy in Calgary - Alberta Health Services and Dr. Helen Murphy in Cambridge, U.K., who are co-principal investigators overseeing Canadian and international sites. The story also provides a trial patient perspective and her experience.  And last but not least, a great segment on JDRF CCTN and a quote from Minister Gary Goodyear supporting JDRF’s efforts.

Read More